Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Supplementary Protection Certificate Mechanism Needs To Go, Say Campaigners

Executive Summary

A group of more than 30 NGOs has urged the European Commission to consider abolishing the system of granting supplementary protection certificates to pharmaceutical companies, saying it delays generic competition and affects the availability of affordable medicines. A UK-based patent attorney, however, says the assertions made by the NGOs are not supported by the evidence.

Advertisement

Related Content

Consultation To Help Determine Whether EU SPC Framework Fit For Purpose
Consultation To Help Determine Whether EU SPC Framework Fit For Purpose
France In Talks With BeNeLuxA Access To Meds Coalition; Group Plans Expansion Beyond EU
More European Countries Agree To Swap Pricing Info And Negotiate Prices
EC To Consult On Ways To Boost Generics & Biosimilars Industry, Introduce EU-wide SPC
'Skyrocketing' Drug Prices, Access And Availability In Line For EU Scrutiny

Topics

Advertisement
UsernamePublicRestriction

Register

PS121535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel